With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13130-79-5,1-Bromoisoquinolin-3-amine,as a common compound, the synthetic route is as follows.
To a stirred solution of 3-amino-l-bromoisoquinoline (444 mg, 2.00 mmol) in anhydrous dimethylformamide (10 mL) was added sodium hydride (60%, unwashed, 96 mg, 2.4 mmol) in one portion. The mixture was stirred at 25 C for 5 min before 2- bromoethyl ether (90%, 250 mu,, 2.00 mmol) was added. The mixture was stirred further at 25 C for 5 h and at 75 C for 72 h before it was cooled to 25 C, quenched with saturated ammonium chloride solution and diluted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over Na2S04, filtered andconcentrated. Purification of the residue on silica gel eluting with 0% to 70% ethyl acetate/hexanes afforded Cap-143, step a as a yellow solid (180 mg, 31%). Rt = 1.75 min (Cond.-MS-Wl); 90% homogenity index; LCMS: Anal. Calc. for [M+H C13H14BrN20: 293.03; found: 293.04.
13130-79-5, As the paragraph descriping shows that 13130-79-5 is playing an increasingly important role.
Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; PACK, Shawn, K.; TYMONKO, Steven; PATEL, Bharat, P.; NATALIE, JR., Kenneth, J.; BELEMA, Makonen; WO2011/59850; (2011); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem